An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Differences in sleep patterns, which can be objectively measured with wrist-worn accelerometers, are the norm among patients with lifetime psychiatric conditions.
Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.
Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
This systematic review and meta-analysis of randomized controlled trials assessed the efficacy and safety of gabapentin and duloxetine for treating patients with painful diabetic peripheral neuropathy.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
The FDA has cleared Nexstim's NBT system for the treatment of major depressive disorder.
Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.